Logo Image

Shorts

Evolution of Antiamyloid Therapies in Alzheimer Disease
1:21
Evolution of Antiamyloid Therapies in Alzheimer Disease
9 months ago
by
Robert Alexander, MD(+1 more)
Emerging Therapies in Neuromuscular Disorders
1:13
Emerging Therapies in Neuromuscular Disorders
9 months ago
by
Amit Sachdev, MD, MS(+1 more)
Integrating AI and Translational Science to Advance ALS Care
1:08
Integrating AI and Translational Science to Advance ALS Care
9 months ago
by
Crystal Yeo, MD, PhD(+1 more)
Envisioning the Future of Epilepsy Care for Patients With Depressive Symptoms
1:53
Envisioning the Future of Epilepsy Care for Patients With Depressive Symptoms
9 months ago
by
Cortney Wolfe-Christensen, PhD(+2 more)
At-Home Autoinjector of Lecanemab for Alzheimer Disease
1:10
At-Home Autoinjector of Lecanemab for Alzheimer Disease
9 months ago
by
Robert Przybelski, MD, MS (+1 more)
Advancements in Alzheimer Disease Biomarkers
1:34
Advancements in Alzheimer Disease Biomarkers
9 months ago
by
Nicholas Ashton, PhD(+1 more)
Lessons on Strong Recruitment From the U.S. POINTER Study
1:28
Lessons on Strong Recruitment From the U.S. POINTER Study
9 months ago
by
Jessica Langbaum, PhD(+1 more)
Biomarker Use and Targeted Treatments in Alzheimer Disease
1:21
Biomarker Use and Targeted Treatments in Alzheimer Disease
9 months ago
by
Aaron Burstein, PharmD(+1 more)
Using Digital Tools to Shift Azheimer Detection Upstream
1:08
Using Digital Tools to Shift Azheimer Detection Upstream
9 months ago
by
John Showalter, MD, MSIS (+1 more)
Pioneering Alzheimer Disease Neuroimaging and Neuropathology
1:28
Pioneering Alzheimer Disease Neuroimaging and Neuropathology
9 months ago
by
Takeshi Iwatsubo, MD, PhD(+1 more)
Seronegative NMOSD in New Diagnostic Criteria
1:03
Seronegative NMOSD in New Diagnostic Criteria
9 months ago
by
Álvaro Cobo-Calvo, MD, PhD(+1 more)
The Role of Virtual Reality in MS Rehabilitation
1:07
The Role of Virtual Reality in MS Rehabilitation
9 months ago
by
Tobias Nef, PhD(+1 more)
Angela Lek, PhD
0:53
Previewing 2026 MDA Conference
9 months ago
by
Angela Lek, PhD(+1 more)
Rituximab Shows Promise as Long-Term Treatment for Relapsing MS
1:02
Rituximab Shows Promise as Long-Term Treatment for Relapsing MS
9 months ago
by
Louie Pasculli(+1 more)
Enhancing ALS Care Through Clinical Trial Readiness
1:20
Enhancing ALS Care Through Clinical Trial Readiness
9 months ago
by
Brian Lin, PhD(+1 more)
Key Updates Proposed for Revised NMOSD Diagnostic Criteria
1:03
Key Updates Proposed for Revised NMOSD Diagnostic Criteria
9 months ago
by
Shailee Samir Shah, MD(+1 more)
Robert J. Fox, MD
1:03
Phase 2 Data of Vidofludimus Calcium in Progressive MS
9 months ago
by
Robert Fox, MD(+1 more)
Charisse Winston-Gray, PhD, MSc
1:22
Strategies for Increasing Diversity in Brain Aging Research
9 months ago
by
Charisse Winston-Gray, PhD, MSc(+1 more)
Media-Driven Misconceptions of Narcolepsy
1:20
Media-Driven Misconceptions of Narcolepsy
10 months ago
by
Julie Flygare, JD(+1 more)
Ethel Ciampi, MD, MSc
0:30
Barriers to Early Diagnosis and Access to Care in MS
a year ago
by
Ethel Ciampi, MD, MSc(+1 more)
Collaboration Within the ALS Community
1:30
Collaboration Within the ALS Community
a year ago
by
Jinsy A. Andrews, MD, MSc(+1 more)
Safety Considerations for Kygevvi in Tk2d
1:30
Safety Considerations for Kygevvi in Tk2d
a year ago
by
Fabian Somers, PhD(+1 more)
Data Backing First Treatment for Tk2d
1:30
Data Backing First Treatment for Tk2d
a year ago
by
Fabian Somers, PhD(+1 more)
Training the Next Neuromuscular Specialists
1:30
Training the Next Neuromuscular Specialists
a year ago
by
John Norbury, MD(+1 more)
Evolving Landscape of Myasthenia Gravis Treatment
1:15
Evolving Landscape of Myasthenia Gravis Treatment
a year ago
by
Leila Darki, MD(+1 more)
Aerobic Exercise and Promoting Remyelination in MS
1:05
Aerobic Exercise and Promoting Remyelination in MS
a year ago
by
Lindsey Wooliscroft, MD, MS(+1 more)
MDS 2025: Learning From Progress in Other Disease States
1:12
MDS 2025: Learning From Progress in Other Disease States
a year ago
by
Lorraine Kalia, MD, PhD(+1 more)
MDS 2025: Biologically Defining Parkinson Disease
1:16
MDS 2025: Biologically Defining Parkinson Disease
a year ago
by
Tanya Simuni, MD, FAAN(+1 more)
MDS 2025: Environmental Exposures and PD
1:32
MDS 2025: Environmental Exposures and PD
a year ago
by
Web Ross, MD(+1 more)
MDS 2025: Novel Therapeutics and Biomarkers for PD
0:53
MDS 2025: Novel Therapeutics and Biomarkers for PD
a year ago
by
Veronica Santini, MD, MA(+1 more)